Neoleukin Therapeutics, Inc. (NLTX)
| Market Cap | 45.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.09M |
| Shares Out | 42.50M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,144,804 |
| Open | 1.13 |
| Previous Close | 1.11 |
| Day's Range | 1.05 - 1.16 |
| 52-Week Range | 0.80 - 10.56 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 14.86 (+1,275.9%) |
| Earnings Date | Aug 4, 2022 |
About NLTX
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neole... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for NLTX stock is "Buy." The 12-month stock price forecast is 14.86, which is an increase of 1,275.93% from the latest price.
News
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein the...
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein the...
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annua...
- NL-201 demonstrates antitumor activity in preclinical B-cell lymphoma models -
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Mee...
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 –
Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (...
- NL-201 plus pembrolizumab to be evaluated in advanced solid tumor patients - - Combination testing anticipated to begin in 2022 -
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd...
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy and anti-PD1 combination in non-Hodgkin lymphoma ...
Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer's 36th Annual Meeting ...
SEATTLE, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Can...
SEATTLE, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...
Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
SEATTLE, May 26, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein the...
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
- Entered clinical development with first patient dosed in Phase 1 Trial of NL-201 -
Neoleukin's IL-2 Agonist Candidate Cleared To Start Phase 1 Trial In Solid Tumors
The FDA has removed the clinical hold related to Neoleukin Therapeutics Inc (NASDAQ: NLTX) investigational new drug application, to begin a Phase 1 program of its cancer immunotherapeutic candidate, NL-...
Neoleukin Therapeutics Announces Year End 2020 Financial Results
- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 -
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein t...
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX
New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ: NLTX). Su c...
SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC is investigating whether Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) ("Neoleukin" or the "Company") complied with federal se...
Why Neoleukin Therapeutics Stock Is Down Today
The company is experiencing regulatory headwinds.
Aquinox (NLTX) Moves to Buy: Rationale Behind the Upgrade
Aquinox (NLTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immuno...
SEATTLE, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...
Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference
SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein th...